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a b s t r a c t
Sympathetic ﬁbres maintain some forms of neuropathic pain, but the underlying mechanisms are poorly
understood. Therefore, this study investigated the possible involvement of transient receptor potential
ankyrin 1 (TRPA1) and the role of the sympathetic nervous system (involved in sympathetically
maintained neuropathic pain) in a model of neuropathic pain induced by sciatic nerve chronic
constriction injury (CCI) in mice. Systemic injection of the selective TRPA1 antagonist HC-030031
reversed the mechanical and cold allodynia that was induced by sciatic nerve chronic constriction injury
(CCI). Nerve injury also sensitised mice to nociception, which was induced by the intraplantar injection
of a low dose of the TRPA1 agonist allyl isothiocyanate without changing TRPA1 immunoreactivity in the
injected paw. Furthermore, chemical sympathectomy produced by guanethidine largely prevented CCI-
induced mechanical and cold allodynia. CCI also induced a norepinephrine-triggered nociception that
was inhibited by an α-adrenoceptor antagonist, norepinephrine transporter block and monoamine
oxidase inhibition. Finally, the peripheral injection of HC-030031 also largely reduced CCI-induced
norepinephrine nociception and mechanical or cold allodynia. Taken together, the present ﬁndings
reveal a critical role of TRPA1 in mechanical and cold hypersensitivity and norepinephrine hypersensi-
tivity following nerve injury. Finally, our results suggest that TRPA1 antagonism may be useful to treat
patients who present sympathetically maintained neuropathic pain.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Neuropathic pain is a debilitating condition that is poorly
understood and often untreatable. It is caused by a lesion or
disease of the somatosensory nervous system (Treede et al., 2008).
Pain after neuropathy is the consequence of a complex interplay of
mechanisms in the peripheral and central nervous systems that
are among the most intractable of pain syndromes (Woolf and
Mannion, 1999). Neuropathic pain is often resistant to common
therapeutic interventions. Common complaints of neuropathic
pain patients include spontaneous pain and painful hypersensitiv-
ity to mechanical, thermal and chemical stimuli (Baron, 2006). The
sympathetic nervous system may mediate some types of neuro-
pathic pain, as demonstrated by pain relief that is achieved by
sympathetic blockade or antagonism of α-adrenoceptors (Baron,
2006). Moreover, some neuropathies cause hypersensitivity to
norepinephrine, which may stimulate nociceptors and induce
spontaneous pain (Ali et al., 2000; Drummond, 2010; Torebjork
et al., 1995; Xanthos et al., 2008). Previous data suggest a
pathological interaction between sympathetic and afferent neu-
rons in the skin because the intensity of spontaneous pain and the
spatial distribution of mechanical dynamic and punctate hyper-
algesia are greater during high sympathetic activity than during
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low activity (Baron, 2006; Baron et al., 2002). Furthermore, the
interaction between sympathetic and afferent neurons in deep
somatic tissues may also play an important role in the pathophy-
siology of sympathetically maintained pain (Drummond et al.,
1991). However, the mechanisms involved in sympathetically
maintained neuropathic pain are poorly understood.
Transient receptor potential ankyrin 1 (TRPA1) is a non-selective,
calcium-permeable cation channel that is usually expressed in a
subset of small diameter primary afferent nerve ﬁbres jointly with
the TRP vanilloid 1 receptor (TRPV1) (Pertovaara and Koivisto, 2011;
Story et al., 2003). This channel is relevant for the detection of
nociceptive stimuli, and it may be activated by various exogenous
irritants, such as allyl isothiocyanate from mustard oil, and several
endogenous reactive species, such as hydrogen peroxide and
unsaturated aldehydes, that are produced during tissue damage
and neuropathy (Andersson et al., 2008; Andre et al., 2008;
Macpherson et al., 2007; Trevisani et al., 2007). Moreover, the
TRPA1 channel is activated and sensitised by different compounds
that are produced during tissue damage (e.g., inﬂammation and
neuropathic pain), such as adenosine triphosphate (ATP, via the
activation of P2X3 receptor) (Krimon et al., 2013) and nerve growth
factor (NGF) (Obata et al., 2005). Furthermore, TRPA1 may be
important to the development of cold allodynia and mechanical
hyperalgesia caused by trauma-, diabetes- or chemotherapy-
induced neuropathy (Caspani et al., 2009; Eid et al., 2008; Nassini
et al., 2011; Obata et al., 2005; Wei et al., 2009). Notably, it has been
suggested that reactive oxygen species and reactive aldehydes
generated during norepinephrine uptake and metabolism could
be involved in neuropathic pain maintenance (Dina et al., 2008).
However, the inﬂuence of TRPA1 on neuropathic pain mediated by
the sympathetic nervous system is currently unknown. Therefore, we
hypothesised that TRPA1 activation by reactive species that are
generated during sympathetic activation could be relevant for the
maintenance of sympathetically mediated neuropathic pain. This
study investigated the possible involvement of the TRPA1 receptor in
a mouse model of sympathetically mediated neuropathic pain.
2. Materials and methods
2.1. Animals
Experiments were conducted using male adult Swiss mice
weighing 30–35 g that were bred in the Federal University of
Santa Maria animal house. Mice were maintained in home cages
under a 12:12 h light–dark cycle (lights on 06:00 h) at a constant
room temperature (2272 1C). The animals were acclimated in the
laboratory for at least 2 h before testing. The experiments were
performed with the approval of the Ethics Committee of the
Federal University of Santa Maria (Process number: 164/2011)
and performed in accordance with the current guidelines for the
care of laboratory animals and the ethical guidelines for investiga-
tions involving experiments on conscious animals (Zimmermann,
1983). The total number of animals (316 animals) and the
nociceptive stimuli used in this study were the minimum neces-
sary to demonstrate consistent effects of drug treatments. The
speciﬁc number of animals used for each experiment is indicated
in Section 3 and ﬁgure legends. Animal allocation to treatment
groups was randomised by a computer using Research Randomi-
zer (www.randomizer.org). Blinded investigators performed the
behavioural observations.
2.2. Drugs and reagents
All reagents were obtained from Sigma Chemical Company (St.
Louis, MO, USA) unless indicated. HC-030031 (2-(1,3-dimethyl-2,6-
dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)
acetamide) was synthesised as previously described (Andre et al.,
2008). Acetone was purchased from Vetec (Rio de Janeiro, Brazil).
Allyl isothiocyanate, HC-030031 and propranolol stock solutions
were prepared in dimethyl sulfoxide (DMSO, 5%), Tween-80 (10%)
and phosphate-buffered saline (PBS, 137 mM NaCl and 10 mM
phosphate buffer, pH 7.4). The stock solutions of the other drugs
were prepared in PBS. All stock solutions were diluted in PBS to the
desired concentration just before use. For the actual drug admin-
istration, the ﬁnal concentration of DMSO and Tween-80 did not
exceed 0.5%, which did not cause any detectable effects per se.
2.3. Neuropathic pain model
For the induction of chronic mononeuropathy, mice were ﬁrst
anesthetised by an intraperitoneal (i.p.) injection of 90 mg/kg of
ketamine plus 3 mg/kg of xylazine hydrochloride. Neuropathy was
induced by chronic constriction injury (CCI) of the sciatic nerve
using a similar procedure previously described for rats (Bennett
and Xie, 1988) and adapted for mice (Sommer et al., 1998). Three
loosely constrictive ligatures were placed around the right sciatic
nerve under anaesthesia. In sham surgery, animals were anesthe-
tised, and the sciatic nerve was exposed without performing
constriction. Sham-operated animals were used as neuropathy
controls. Naïve animals were neither anesthetised nor operated,
and they were used as surgery controls. Nociceptive tests were
performed seven days after the procedures.
2.4. Measurement of mechanical hyperalgesia
We utilised mechanical hyperalgesia as a parameter of noci-
ception, which was characterised by a signiﬁcant decrease in the
mechanical paw withdrawal threshold (PWT) compared with the
baseline values. The measurement of mechanical PWT was per-
formed using an up-and-down protocol as described previously
(Chaplan et al., 1994). Brieﬂy, mice were ﬁrst acclimated in
individual clear plexiglas boxes (9711 cm3) on an elevated
wire mesh platform to allow access to the plantar surface of the
right hind paw. Next, von Frey ﬁlaments of increasing stiffness
(0.02, 0.07, 0.16, 0.4, 1.4, and 4 g) were applied to the hind paw
plantar surfaces with enough pressure to bend the ﬁlament,
starting with the 0.4 g ﬁlament. The absence of paw lifting after
5 s led to the use of the next stiffer ﬁlament, whereas paw lifting
indicated a positive response and led to the use of the next weaker
ﬁlament. This protocol continued until a total of six measurements
were taken or four consecutive positive or negative responses
occurred. All measurements were performed on the paw ipsilat-
eral to the surgical or sham procedure. The 50% mechanical PWT
response was calculated from the resulting scores as described
previously (Dixon, 1980). The 50% PWT was expressed in grams
(g), and it was evaluated before (baseline) and after treatment or
surgical procedures at different time points (0.5–4 h), as indicated
in the protocols.
2.5. Measurement of cold allodynia
We utilised cold allodynia as another nociception parameter,
which was characterised by a nocifensive reaction of animals after
evaporative cooling of topically applied acetone (Caspani et al.,
2009; Nassini et al., 2011). After the measurement of PWT, 20 ml of
acetone was applied to the dorsal hind paw ipsilateral to the
injury, and the resulting behaviour was assigned an arbitrary
score. A score of 0 indicated no response, 0.5 a licking response,
1 ﬂinching and brushing of the paw, 2 strong ﬂinching, and
3 strong ﬂinching and licking. Mouse behaviour was observed
during the ﬁrst 30 s before (baseline) acetone application, after
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acetone application, and at different time points (0.5–4 h) as
indicated in the protocols after different treatments or surgical
procedure.
2.6. Role of the TRPA1 receptor on neuropathic nociception induced
by CCI
We veriﬁed the role of the TRPA1 receptor on CCI-induced
neuropathic nociception by investigating the possible antinoci-
ceptive or nociceptive effects of a TRPA1 receptor antagonist and
agonist. In addition, we investigated alterations in TRPA1 immu-
noreactivity in control or nerve-injured mice.
2.6.1. Effect of selective TRPA1 antagonist treatment on CCI-induced
mechanical and cold allodynia
The involvement of TRPA1 in CCI-induced allodynia was eval-
uated using the selective TRPA1 antagonist HC-030031. Seven days
after surgery, mice were treated with HC-030031 (10, 30 or
100 mg/kg, i.p.) (da Costa et al., 2010) or vehicle (0.25% DMSO,
0.5% Tween-80 in PBS, i.p.). The effect of the drug on mechanical
hyperalgesia or cold allodynia was examined 1 h before treatment
and at different time points (0.5–4 h) after i.p. HC-030031 treat-
ment. Separate groups of animals were treated with HC-030031
(100 mg/paw) (da Costa et al., 2010) or vehicle (20 ml/paw) via
subcutaneous injection under the dorsal surface of the right hind
paw (intraplantar, i.pl.), and the effect of the drug on mechanical
hyperalgesia or cold allodynia was examined before and 1 h after
treatment.
2.6.2. TRPA1 agonist-induced hypersensitivity
We next investigated whether a low dose of a TRPA1 agonist
could induce spontaneous nociception in nerve-injured mice.
Spontaneous nociception induced by the TRPA1 receptor agonist
allyl isothiocyanate was performed as previously described
(Andrade et al., 2008). The animals were placed individually in
chambers (transparent glass cylinders 20 cm in diameter) and
were allowed to adapt to the chambers for 10 min before treat-
ment. After the adaptation period, 20 ml of a sub-effective dose of
allyl isothiocyanate (100 ng/paw) (Andrade et al., 2008) was
injected i.pl. into the right hind paw. Separate groups of animals
received an i.pl. injection of the appropriate vehicle and were used
as controls. After this drug challenge, mice were observed indivi-
dually for 5 min, and the amount of time spent licking, ﬂinching or
lifting the injected paw was measured with a chronometer. These
behaviours were considered indicative of nociception. A separate
group of animals was also treated with HC-030031 (100 mg/kg, i.
p.) or vehicle (0.25% DMSO, 0.5% Tween-80 in PBS, i.p.) 1 h before
AITC i.pl. injection.
2.6.3. TRPA1 immunoreactivity analysis
Immunoreactivity to the TRPA1 receptor was assessed using
western blot analysis as previously described (Trevisan et al.,
2014). The right hind paw skin (the site of nociceptive measures)
and the sciatic nerve (the site of nerve injury) were quickly
isolated and homogenised (tissue homogeniser for 0.1–50 ml; type
EL-770; Insight Equipamentos, Pesquisa e Ensino; Ribeirão Preto;
Brazil) in 400 ml or 200 ml, respectively, of ice-cold in a lysis buffer
containing 10 mM HEPES, pH 7.9, 10 mM KCl, 2 mM MgCl2, 1 mM
ethylenediamine tetraacetic acid (EDTA), 1 mM NaF, 10 mg/ml
aprotinin, 10 mM β-glycerophosphate, 1 mM phenylmethanesul-
phonyl ﬂuoride, 1 mM DL-dithiothreitol (DTT) and 2 mM of
sodium orthovanadate and incubated for 15 min on ice. After
centrifugation (3000g for 30 min at 4 1C), the supernatant was
collected. The protein content was determined using the method
of Coomassie Dye (Bradford, 1976) with bovine serum albumin as a
standard. Next, 50 and 30 mg of protein from the sciatic nerve or
hind paw homogenised samples, respectively, were mixed with
loading buffer (200 mM Tris, 10% glycerol, 2% SDS, 2.75 mM β-
mercaptoethanol and 0.04% bromophenol blue) and boiled for
10 min. The proteins were separated in 10% sodium dodecyl
sulphate-polyacrylamide gels (SDS-PAGE) and transferred to poly-
vinylidene diﬂuoride membranes according to the manufacturer's
instructions (PerkinElmer, Waltham, MA, USA). The membranes
were processed using a SNAP I.D. system (Millipore, Temecula, CA,
USA), blocked with 1% BSA in TBS-T (0.05% Tween 20 in Tris-borate
saline) and incubated for 10 min with a speciﬁc rabbit polyclonal
IgG antibody to anti-TRPA1 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) diluted 1:150 in TBS-T. The blots were washed thrice with
TBS-T followed by incubation with the secondary antibody
(1:3000) for 10 min. For measurement, the chemiluminescence
system (ECL Western Blotting Systems, GE Healthcare, Little
Chalfont, BKM, UK) was used and visualised using the ChemiDocTM
XRSþ System (BioRad, Life Technologies, Carlsbad, CA, USA). To
assess the quality of the separation, the same membranes were
stained with mouse actin antibody (Sigma, St. Louis, MO, USA)
1:3000. Then, the membranes were incubated with respective
secondary antibody conjugated with peroxidase following the
same protocol described above. The bands shown are representa-
tive of the groups. The quantiﬁcation was performed by normal-
isation with control group (medium). The TRPA1 western blots
presented a faint background that was corrected during image
analysis.
2.7. Role of sympathetic nervous system on CCI-induced neuropathic
nociception
We investigated the role of the sympathetic nervous system in
CCI-induced neuropathic nociception by investigating the effect of
chemical sympathectomy on the cold allodynia or mechanical
hyperalgesia caused by CCI and the possible nociceptive effect of
norepinephrine in control and nerve-injured mice.
2.7.1. The role of sympathetic ﬁbres in CCI-induced nociception
Chemical sympathectomy was produced by the treatment of mice
with guanethidine (30 mg/kg, i.p.) as described previously (Ferreira et
al., 2005) to investigate the role of sympathetic ﬁbres in CCI-induced
nociception. Treatment was administered on days 4, 5 and 6 after CCI
induction. Seven days after CCI induction (1 day after the last
guanethidine injection), mechanical hyperalgesia and cold allodynia
were measured as described above.
2.7.2. Norepinephrine-induced spontaneous nociception
Spontaneous nociception induced by norepinephrine was per-
formed as previously described (Xanthos et al., 2008) with minor
modiﬁcations. Seven days after sham or nerve-injury surgery, the
animals were placed individually in chambers (transparent glass
cylinders 20 cm in diameter) and were allowed 10 min for adap-
tion before treatment. After the adaptation period, 20 ml of the
adrenergic receptor agonist norepinephrine (30 ng/paw) was
injected i.pl. under the dorsal surface of the right hind paw.
Separate groups of animals received an i.pl. injection of the
appropriate vehicle and were used as controls. After challenge,
the mice were observed individually for 5 min, and the amount of
time spent licking, ﬂinching or lifting the injected paw was
measured with a chronometer. These behaviours were considered
indicative of nociception.
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2.8. Investigation of some mechanisms involved in norepinephrine-
induced nociception in nerve-injured mice
Distinct groups of animals were treated with different classes
of drugs that were locally co-administered with norepinephrine
(30 ng/paw, i.pl.) to investigate some of the possible mechanisms
through which the peripheral injection of norepinephrine causes
nociception in nerve-injured mice. The following drugs were co-
administered with norepinephrine: the α-adrenoceptor antagonist
phentolamine (100 ng/paw), the β-adrenoceptor antagonist pro-
pranolol (300 pg/paw), the norepinephrine transporter (NET)
inhibitor desipramine (100 ng/paw), the monoamine oxidase-A
inhibitor (MAO-A) clorgyline (100 ng/paw) and the TRPA1 receptor
antagonist HC-030031 (100 mg/paw). A separate group of animals
was also treated with HC-030031 (100 mg/kg, i.p.) or its vehicle
1 h before norepinephrine injection. The dosage choice for each
drug was based on previous data described in the literature
(Xanthos et al., 2008; Ferreira et al., 2005; da Costa et al., 2010)
or on preliminary experiments performed in our laboratory.
2.9. Statistical analyses
The results are presented as the means7S.E.M., except for the
cold allodynia scores, which are reported as medians followed by
their 25th and 75th percentiles. The inhibition percentages are
reported as the means7S.E.M., which were calculated based on
the responses of the control group. Statistical analyses were
performed using the GraphPad Prism 4.0 software. The signiﬁ-
cance of differences between groups was evaluated with Mann–
Whitney's test or a Kruskal–Wallis test followed by Dunn's test (for
Fig. 1. TRPA1 antagonist reduced neuropathy-induced mechanical allodynia in
mice. (A) 50% paw withdrawal thresholds (PWT) before (baseline) and 7 days after
procedures in naïve, sham and chronic constriction-injured (CCI) mice (n¼7 each
group). ***Po0.001, compared with the sham group (one-way ANOVA followed by
Student Newman–Keuls' test). (B) Time-course of PWT in neuropathic mice treated
with HC-030031 (100 mg/kg, i.p.) or vehicle (10 ml/kg, i.p.) (n¼7 each group).
**Po0.01, compared to baseline values; #Po0.05 and ##Po0.01, compared with
vehicle-treated animals (two-way ANOVA followed by Bonferroni's test). (C) Dose–
response curve for the anti-allodynic effect of HC-030031 (10–100 mg/kg, i.p.)
(n¼7 each group). **Po0.01, compared to baseline, ##Po0.01, compared with
vehicle-treated animals (one-way ANOVA followed by Student Newman–Keuls'
test). Data are expressed as the meansþS.E.M.
Fig. 2. TRPA1 antagonist reduced neuropathy-induced cold allodynia in mice.
(A) Nocifensive reaction scores for the right hind paw of animals after evaporative
cooling of acetone before (baseline) and 7 days after the procedure in naïve, sham
and chronic constriction-injured (CCI) mice (n¼10 each group). **Po0.001,
compared with sham group (Kruskal–Wallis followed by Dunn's test). (B) Time-
course of HC-030031 (100 mg/kg, i.p.) and vehicle (10 ml/kg) effects on cold
allodynia in neuropathic mice (n¼10 each group). **Po0.01, compared with
baseline values; #Po0.05, compared with respective vehicle-treated animals
(Mann–Whitney's test). Data are expressed as the medians7 interquartile ranges.
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the cold allodynia results) along with an unpaired Student's t-test
and one-way analysis of variance (ANOVA). ANOVA was followed
by a Student–Newman–Keuls' (SNK) test or two-way ANOVA
followed by Bonferroni's test (for mechanical allodynia and spon-
taneous nociception results). Po0.05 was considered signiﬁcant.
3. Results
3.1. Antinociceptive effect of the selective TRPA1 antagonist
HC-030031 on CCI-induced mechanical hyperalgesia
Fig. 1A depicts the 50% paw withdrawal thresholds (PWT) of
naïve, sham, and nerve-injured mice. There was no difference in
the PWT values between groups before the procedure or between
naïve and sham-operated mice 7 days after the procedure. How-
ever, CCI of the sciatic nerve induced a marked mechanical
allodynia compared with sham surgery mice 7 days after lesion
creation (Fig. 1A).
The mechanical allodynia produced by nerve injury was main-
tained throughout the experimental period in vehicle-treated mice
(Fig. 1B). However, the systemic injection of HC-030031 (100 mg/
kg, i.p.) reversed CCI-induced mechanical allodynia from 0.5 to 2 h
after injection, with a complete inhibition 1 h after treatment
(Fig. 1B). The higher dose (100 mg/kg), but not the lower doses (10
or 30 mg/kg, i.p.), of injected HC-030031 reduced mechanical
allodynia in nerve-injured mice (Fig. 1C). Notably, HC-030031
treatment (100 mg/kg, i.p.) did not alter the mechanical thresholds
of sham-operated mice (results not shown). Therefore, the
100 mg/kg (i.p.) HC-030031 dose was used in subsequent tests.
Seven animals were used per group in Fig. 1, with a total of 70
animals.
3.2. Antinociceptive effect of the selective TRPA1 antagonist
HC-030031 on CCI-induced cold allodynia
Fig. 2A depicts the nocifensive reactions of the right hind paw
of animals after evaporative cooling of acetone. The topical
application of acetone did not induce nociception in naïve, sham,
and nerve-injured mice before the procedure (baseline) or in naïve
or sham animals 7 days after the surgical procedure. In contrast,
CCI of the sciatic nerve induced cold allodynia compared to sham
surgery in mice after 7 days (Fig. 2A).
Systemic treatment with HC-030031 (100 mg/kg, i.p.) almost
completely reversed the cold allodynia induced by CCI compared
with the vehicle group at 1 and 2 h after administration (Fig. 2B).
HC-030031 treatment did not alter the acetone scores in sham-
operated animals (results not shown). Ten animals were used per
group in Fig. 2, with a total of 50 animals.
3.3. TRPA1 agonist-induced nociception in neuropathic mice
The sensitivity of peripheral TRPA1 receptors in neuropathic
mice was investigated by examining the spontaneous nociception
induced by a receptor agonist (Fig. 3). The intraplantar injection of
a low dose of the TRPA1 agonist AITC (100 ng/paw) did not induce
nociception in sham-operated mice, but it did cause an intense
nociceptive response in mice seven days after CCI (Fig. 3A).
Fig. 3. TRPA1 agonist-induced nociception in neuropathic mice. (A) Effect of intraplantar AITC (100 ng/paw) and vehicle injection on nociception time in chronic
constriction-injured (CCI) and sham-operated mice (n¼7). ***Po0.01 compared with respective vehicle-treated group (unpaired t test). (B) Antinociceptive effect of HC-
030031 (100 mg/kg, i.p.) pre-treatment on the nociception caused by i.pl. injection of AITC (100 ng/paw) in neuropathic mice (n¼7 each group). ***Po0.001 compared with
vehicle-treated group (unpaired t test). TRPA1 immunoreactivity in the right hind paw (C) and the injured sciatic nerve (D) seven days after surgery (n¼4 each group).
Lane 1, control (sham mice). Lane 2, CCI mice. Western blot results were expressed as % of control. The representative β-actin protein bands demonstrates equal loading.
**Po0.01 compared with sham group (unpaired t test). Data are expressed as the meansþS.E.M.
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Furthermore, pre-treatment with HC-030031 (100 mg/kg, i.p.)
largely prevented (9172% inhibition) the spontaneous nocicep-
tion induced by AITC in nerve-injured mice (Fig. 3B). Seven
animals were used per group in Fig. 3A and B, with a total of 28
animals.
3.4. Detection of TRPA1 immunoreactivity in neuropathic mice
We next investigated whether the nociceptive response to the
TRPA1 agonist could be due to an increase in TRPA1 expression in
the right hind paw (local nociception measurement) or sciatic
nerve (location of the nerve injury). We observed that TRPA1
immunoreactivity in the hind paw ipsilateral to the nerve lesion
was not different between the sham and nerve-injured mice
(Fig. 3C). However, CCI signiﬁcantly reduced (44710%) TRPA1
immunoreactivity in the sciatic nerve seven days after lesion
creation compared to the sham-operated group (Fig. 3D). Four
animals were used per group in Fig. 3C and D, with a total of
8animals.
3.5. CCI-induced nociception is sympathetically maintained
The chemical sympathectomy produced by guanethidine
(30 mg/kg, i.p., 3 days before CCI) largely prevented CCI-induced
mechanical hyperalgesia (Fig. 4A) and cold allodynia (Fig. 4B); the
mechanical threshold and acetone scores similar to baseline values
(before the surgical procedure). The same guanethidine treatment
did not alter either the mechanical thresholds or acetone scores in
sham-operated mice (results not shown).
Next, we investigated whether nerve-injured animals had a
nociceptive response to norepinephrine. An intraplantar injection
of norepinephrine (30 ng/paw) induced only a few spontaneous
nociceptive behaviours in sham-operated animals (8.073.2 s of
response), which were not different from the responses to vehicle
(PBS) in sham and nerve-injured mice (5.172.0 and 4.472.3 s of
response, respectively) (Fig. 4C). In contrast, an intraplantar injec-
tion of norepinephrine (30 ng/paw) produced a marked nociceptive
response in animals seven days after CCI compared to the PBS group
(39.377.1 and 8.073.2 s of response, respectively) (Fig. 4C). Eight
animals were used per group in Fig. 4, with a total of 48 animals.
3.6. Study of the peripheral mechanisms involved in NE-induced
nociception
First, we examined the role of adrenoceptors and norepinephrine
uptake and degradation on norepinephrine-induced nociception
using receptor antagonists, transporter and enzyme inhibitors. The
co-administration of the α-adrenoceptor antagonist phentolamine
(100 ng/paw), but not the β-adrenoceptor antagonist propranolol
(300 pg/paw), only somewhat, but signiﬁcantly, inhibited (2477%)
norepinephrine-induced nociception (30 ng/paw) (Fig. 5A and B).
Furthermore, co-administration with the selective norepinephrine
transporter inhibitor desipramine (100 ng/paw) or the selective mono-
amine oxidase inhibitor clorgyline (100 ng/paw) largely reduced
(inhibition of 8873% and 9077%, respectively) the nociception
caused by norepinephrine (30 ng/paw) in neuropathic mice (Fig. 5C
and D). Eight animals were used per group in Fig. 5, with a total of 64
animals.
.
3.7. Effect of TRPA1 antagonist in NE-induced nociception, cold and
mechanical allodynia caused by nerve injury
The systemic (100 mg/kg, i.p.) or local (100 mg/paw, i.pl.) injec-
tion of HC-030031 largely reduced (inhibition of 8179 and
6378%, respectively) norepinephrine-induced nociception (30 ng/
paw) in nerve-injured animals (Fig. 6A and B). Peripheral injection
of HC-030031 (100 mg/paw, intraplantar) almost completely abol-
ished the mechanical hyperalgesia and cold allodynia induced by
nerve injury (Fig. 6C and D). Eight animals were used per group in
Fig. 6A–D with a total of 48 animals.
4. Discussion
Neuropathic pain is among the most intractable of pain syn-
dromes (Treede et al., 2008; Woolf and Mannion, 1999). Therefore,
the study of its mechanisms is relevant to the development of more
Fig. 4. CCI-induced nociception is sympathetically maintained. (A, B) Effect of the
chemical sympathectomy produced by guanethidine (30 mg/kg, i.p.) in mechanical
(A) and cold (B) allodynia-induced by CCI in mice (n¼8 each group). ***Po0.001
compared with baseline; ###Po0.001 compared with vehicle-treated group
(unpaired t test for A and Mann–Whitney's test for B). Data are expressed as the
meansþS.E.M. (A) or median7 interquartile ranges (B). (C) Effect of intraplantar
norepinephrine (NE, 30 ng/paw) and vehicle injection on nociception in chronic
constriction-injured (CCI) and sham-operated mice (n¼8 each group). ***Po0.01
compared with the respective sham group (unpaired t test).
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effective treatments for neuropathic pain. Sympathetic nervous
system activation and TRPA1 stimulation seem to be important
underlying mechanisms of some neuropathic pain syndromes, but
the relationship between them is unknown. The present study
observed TRPA1 receptor-mediated nociception in a model of
sympathetically maintained pain in mice.
We observed that a selective TRPA1 antagonist largely reversed
both mechanical and cold allodynia induced by chronic sciatic
nerve constriction injury in mice. Our results are consistent with
the literature, which indicates that TRPA1 antagonists and anti-
sense oligonucleotides may reduce mechanical and cold allodynia
produced in rodents by spinal nerve ligation, nerve injury, strep-
tozotocin and oxaliplatin (del Camino et al., 2010; Eid et al., 2008;
Nassini et al., 2011; Obata et al., 2005; Wei et al., 2009). Taken
together, these ﬁndings demonstrate the critical role of the TRPA1
receptor in pain symptoms related to neuropathies of different
aetiologies.
We also investigated the sensitivity of peripheral TRPA1 receptors
in neuropathic mice.We observed that the intraplantar injection of the
TRPA1 agonist allyl isothiocyanate (the main component of mustard
oil) at a dose that did not produce spontaneous nociception in sham-
operated mice caused an intense nociceptive response in mice with
chronic sciatic nerve constriction injury. Moreover, we observed that
HC-030031 treatment abolished AITC-induced nociception, which
indicated that this response was mediated by the TRPA1 receptor.
Although CCI induced a peripheral sensitisation to TRPA1 agonists, we
were unable to detect any differences in the TRPA1 immunoreactivity
in the stimulated hind paw between sham and operated mice.
Therefore, the nociceptive response to a TRPA1 agonist was not due
to an increase in tissue TRPA1 content, but it could be related to an
increase in TRPA1 function. However, additional studies must be
performed to clarify how this phenomenon occurs. In addition, we
observed a signiﬁcant reduction in TRPA1 immunoreactivity in the
sciatic nerve of constriction-injured mice. Similarly, a decrease in
TRPA1 mRNA and protein was reported previously in the dorsal root
ganglion ipsilateral to a chronic constriction injury in mice (Caspani et
al., 2009). These results suggest that cells other than sensory neurons
are also important for TRPA1 expression in paw skin tissue. In fact, it
has been demonstrated that dermal ﬁbroblasts, keratinocytes and
even sympathetic neurons express functional TRPA1 receptors that
could be involved in pain sensitisation (Atoyan et al., 2009; Jain et al.,
2011; Smith et al., 2004).
Some forms of painful peripheral neuropathy are mediated by the
sympathetic nervous system, where pain relief is achieved by
sympatholytic procedures (Baron, 2006). Similar to what has been
observed in rats (Neil et al., 1991), we detected that chemical
sympathectomy produced by guanethidine largely inhibited mechan-
ical hyperalgesia and cold allodynia observed seven days after CCI in
mice, which suggests that CCI is a model for sympathetically
maintained pain. Moreover, CCI may induce sympathetic sprouting
into the ipsilateral dorsal root ganglion and increase plasma norepi-
nephrine levels in rodents one week after injury (Jin et al., 2008;
Ramer et al., 1997). In addition to the analgesic effect of sympatho-
lytic procedures, hypersensitivity to norepinephrine has been taken
as evidence for sympathetically maintained pain (Xanthos et al.,
2008). Consistent with the ﬁndings demonstrating that norepinephr-
ine may stimulate nociceptors and induce spontaneous pain after
nerve injury (Ali et al., 2000; Drummond, 2010; Torebjork et al.,
1995; Xanthos et al., 2008), we found that CCI caused norepinephrine
hypersensitivity. Therefore, CCI in rodents may represent a model of
Fig. 5. Peripheral mechanisms involved in norepinephrine-induced nociception in neuropathic mice. Effect of intraplantar co-administration of phentolamine (100 ng/paw,
A), propranolol (300 pg/paw, B), desipramine (100 ng/paw, C) and clorgyline (100 ng/paw, D) with NE (norepinephrine, 30 ng/paw) in sham-operated and chronic
constriction-injured (CCI) animals (n¼8 each group). ***Po0.001, compared with vehicle-treated sham-operated animals, #Po0.05, ###Po0.001, compared with vehicle-
treated CCI animals (two-way ANOVA). Data are expressed as the meansþS.E.M.
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sympathetically maintained pain, at least one week after initial
induction.
Next, we investigated the mechanisms involved in the hyper-
sensitivity to norepinephrine after nerve injury because they are
poorly understood. Both α1 and α2-adrenoceptors are implicated in
norepinephrine-induced pain in humans and nociception in rats
with neuropathy (Drummond, 2010; Xanthos et al., 2008). Accord-
ingly, we veriﬁed that the α-adrenoceptor antagonist phentolamine,
but not the β-adrenoceptor antagonist propranolol, reduced spon-
taneous nociception to norepinephrine in constriction-injured mice.
The α-adrenoceptor antagonism produced a partial effect, but other
mechanisms are likely involved in this response. It was recently
demonstrated that norepinephrine uptake and metabolism are
involved in alcohol-induced painful peripheral neuropathy in rats
(Dina et al., 2008). Similarly, treatment with selective inhibitors of
the norepinephrine transporter (desipramine) and monoamine
oxidase (clorgyline) largely inhibits the nociception caused by
norepinephrine in nerve-injured mice. Therefore, norepinephrine
metabolism seems to be an important mechanism underlying the
hypersensitivity to norepinephrine after nerve injury.
Norepinephrine metabolism via monoamine oxidase generates
some reactive oxygen species and reactive aldehydes, such as hydro-
gen peroxide and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL),
that are neurotoxic (Burke et al., 2004). Dina et al. (2008) indicated
that catecholamine metabolites contribute to enhanced mechanical
sensitivity of primary sensory afferents, and this possibility was not
excluded although they were not able to clearly prove DOPEGAL
involvement (Dina et al., 2008). In addition, it is important to note that
TRPA1 is implicated in mechanical hyperalgesia and cold allodynia
induced by sciatic nerve injury and that it is activated by several
endogenous reactive species, such as hydrogen peroxide and unsatu-
rated aldehydes from oxidative stress (Andersson et al., 2008;
Trevisani et al., 2007). Therefore, our study indicates that systemic
and peripheral administration of a TRPA1 receptor antagonist almost
abolished norepinephrine-induced nociception in neuropathic mice.
Finally, we demonstrated that the peripheral injection of a TRPA1
receptor antagonist also inhibited CCI-induced mechanical hyperalge-
sia and cold allodynia in mice. Therefore, these data demonstrate the
critical role of peripheral TRPA1 in the induction of painful hypersen-
sitivity in a model of sympathetically maintained pain. Because
primary afferent nociceptors possess the necessary machinery for
uptake and metabolism of catecholamines, and TRPA1 receptors are
largely expressed in peptidergic sensory neurons (Baraldi et al., 2010),
these areas could be the sites where these metabolites bind to
cause pain.
Taken together, the present ﬁndings reveal the critical role of
TRPA1 in mechanical and cold hypersensitivity and the hypersen-
sitivity to norepinephrine after nerve injury. Our results suggest
that TRPA1 antagonists may be useful to neuropathic patients who
present sympathetically maintained pain.
Fig. 6. Peripheral TRPA1 receptor is involved in norepinephrine-induced nociception and cold and mechanical allodynia caused by nerve injury. (A, B) Effect of systemic
(A, 100 mg/kg, i.p.) and peripheral (B, 100 mg/paw, i.pl.) HC-030031 treatment on the nociception caused by NE (norepinephrine, 30 ng/paw, i.pl.) in neuropathic mice (n¼8
each group). ***Po0.001, **Po0.01, compared with vehicle-treated group (unpaired t test). (C, D) Mechanical (C) and cold (D) allodynia induced by CCI in mice before and
1 h after the peripheral treatment with HC-030031 (100 mg/paw, i.pl.) (n¼8 each group). *Po0.05, compared with baseline (two-way ANOVA followed by Bonferroni's
test for C and Kruskal–Wallis followed by Dunn's test for D); #Po0.05, compared with vehicle-treated animals (two-way ANOVA followed by Bonferroni's test for C and
Mann–Whitney's test for D). Data are expressed as the meansþS.E.M. in A–C and as the medians7 interquartile ranges in D.
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